Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma.
Nat Med. 2020 Apr;26(4):577-588. doi: 10.1038/s41591-020-0757-z. Epub 2020 Feb 24.
Nat Med. 2020.
PMID: 32094924
Free PMC article.
Targeting CD47 in Sézary syndrome with SIRPαFc.
Johnson LDS, Banerjee S, Kruglov O, Viller NN, Horwitz SM, Lesokhin A, Zain J, Querfeld C, Chen R, Okada C, Sawas A, O'Connor OA, Sievers EL, Shou Y, Uger RA, Wong M, Akilov OE.
Johnson LDS, et al. Among authors: viller nn.
Blood Adv. 2019 Apr 9;3(7):1145-1153. doi: 10.1182/bloodadvances.2018030577.
Blood Adv. 2019.
PMID: 30962222
Free PMC article.
Clinical Trial.
Item in Clipboard
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, Johnson LD, Linderoth E, Pang X, Winston J, Petrova PS, Uger RA, Viller NN.
Lin GHY, et al. Among authors: viller nn.
PLoS One. 2017 Oct 30;12(10):e0187262. doi: 10.1371/journal.pone.0187262. eCollection 2017.
PLoS One. 2017.
PMID: 29084248
Free PMC article.
Item in Clipboard
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, Uger RA.
Petrova PS, et al. Among authors: viller nn.
Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17.
Clin Cancer Res. 2017.
PMID: 27856600
Item in Clipboard
Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro.
Feng S, Madsen SH, Viller NN, Neutzsky-Wulff AV, Geisler C, Karlsson L, Söderström K.
Feng S, et al. Among authors: viller nn.
Immunology. 2015 Jul;145(3):367-79. doi: 10.1111/imm.12449. Epub 2015 May 19.
Immunology. 2015.
PMID: 25684021
Free PMC article.
Item in Clipboard
Cite
Cite